First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

August 28, 2014 updated by: Bioniche Life Sciences Inc.

Randomized, Double-blind, Multi-center Study Comparing MCC to BCG as First Line Immunotherapy in Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Recurrence or Progression

The purpose of this study is to compare the safety and efficacy of EN3348 (MCC) versus BCG as first line treatment in patients with non-muscle invasive bladder cancer that are at high risk for recurrence or progression.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Laguna Hills, California, United States
      • Los Angeles, California, United States
      • San Diego, California, United States
    • Colorado
      • Englewood, Colorado, United States
    • Florida
      • Daytona Beach, Florida, United States
    • Kansas
      • Overland Park, Kansas, United States
    • Louisiana
      • Shreveport, Louisiana, United States
    • New York
      • Garden City, New York, United States
      • New York, New York, United States
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States
    • South Carolina
      • Myrtle Beach, South Carolina, United States
    • Texas
      • McAllen, Texas, United States
    • Utah
      • Salt Lake City, Utah, United States
    • Virginia
      • Norfolk, Virginia, United States

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • histologically confirmed urothelial carcinoma of the bladder (high grade Ta or T1 papillary lesions, CIS)
  • histologically confirmed diagnosis within 42 days of study treatment
  • life expectancy of greater than 5 years
  • ECOG performance status of 2 or less
  • absence of urothelial carcinoma involving the upper urinary tract or prostatic urethra within 12 months from start of study treatment

Exclusion Criteria:

  • current or previous history of muscle invasive bladder tumors (>T2)
  • current or previous history of lymph node and/or distant metastases from bladder cancer
  • current evidence of squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma of the bladder
  • current systemic cancer therapy
  • previous immunotherapy for bladder cancer
  • previous intravesical chemotherapy treatment
  • contraindication to use BCG of known tolerance to BCG
  • history of malignancy of any organ system within the past 5 years (with the exception of basal cell or squamous cell carcinoma, stage T1 prostate cancer, carcinoma in situ of the cervix, colon polyps)
  • patients who cannot tolerate intravesical administration or intravesical surgical manipulation (cystoscopy or biopsy)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MCC
Intravesical Administration of Mycobacterial Cell-Wall DNA Complex
Biological: Mycobacterial Cell-Wall DNA Complex
8 mg/50 mL (sterile WFI) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
Active Comparator: BCG
Intravesical Administration of Bacillus Calmette-Guerin
Biological: Bacillus Calmette-Guerin
mg/50 mL (sterile saline) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Duration of disease-free survival (time to recurrence, progression or death) in all patients
Time Frame: Baseline, Month 3, 6, 9, 12, 15, 18, 21, and 24
Baseline, Month 3, 6, 9, 12, 15, 18, 21, and 24
Percent of patients who due to study drug-related AEs experience 2 consecutive treatment delays or discontinue due to drug related AEs
Time Frame: Baseline through 24 months
Baseline through 24 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Disease-free survival rate at 2 years
Time Frame: Month 24
Month 24
Frequency, severity, and nature of drug-related AEs
Time Frame: Baseline through 24 Months
Baseline through 24 Months
Duration of progression-free survival (time to progression or death) in all patients
Time Frame: Baseline, Month 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48 and 60
Baseline, Month 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48 and 60
Frequency, severity, and nature of drug-related SAEs
Time Frame: Baseline through 24 months
Baseline through 24 months
Number of treatment delays and their reason
Time Frame: Baseline, Month 3, 6, 9, 12, 15, 18, 21, and 24
Baseline, Month 3, 6, 9, 12, 15, 18, 21, and 24
Frequency, severity and nature of all AEs
Time Frame: Baseline through 24 months
Baseline through 24 months
Number of treatment discontinuations and their reason
Time Frame: Baseline through 24 months
Baseline through 24 months
Duration of Survival (time to death from any cause) in all patients
Time Frame: Baseline through month 60
Baseline through month 60

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bioniche Life Sciences Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2010

Primary Completion (Anticipated)

February 1, 2014

Study Completion (Anticipated)

February 1, 2017

Study Registration Dates

First Submitted

January 25, 2011

First Submitted That Met QC Criteria

January 25, 2011

First Posted (Estimate)

January 26, 2011

Study Record Updates

Last Update Posted (Estimate)

August 29, 2014

Last Update Submitted That Met QC Criteria

August 28, 2014

Last Verified

August 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EN3348-302

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bladder Cancer

Clinical Trials on Mycobacterial Cell-Wall DNA Complex

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe